Cargando…

Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract

BACKGROUND: Metabolic reprogramming is one of the hallmarks of cancer which favours rapid energy production, biosynthetic capabilities and therapy resistance. In our previous study, we showed bitter melon extract (BME) prevents carcinogen induced mouse oral cancer. RNA sequence analysis from mouse t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sur, Subhayan, Nakanishi, Hiroshi, Flaveny, Colin, Ippolito, Joseph E., McHowat, Jane, Ford, David A., Ray, Ratna B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802351/
https://www.ncbi.nlm.nih.gov/pubmed/31638999
http://dx.doi.org/10.1186/s12964-019-0447-y
_version_ 1783460781979860992
author Sur, Subhayan
Nakanishi, Hiroshi
Flaveny, Colin
Ippolito, Joseph E.
McHowat, Jane
Ford, David A.
Ray, Ratna B.
author_facet Sur, Subhayan
Nakanishi, Hiroshi
Flaveny, Colin
Ippolito, Joseph E.
McHowat, Jane
Ford, David A.
Ray, Ratna B.
author_sort Sur, Subhayan
collection PubMed
description BACKGROUND: Metabolic reprogramming is one of the hallmarks of cancer which favours rapid energy production, biosynthetic capabilities and therapy resistance. In our previous study, we showed bitter melon extract (BME) prevents carcinogen induced mouse oral cancer. RNA sequence analysis from mouse tongue revealed a significant modulation in “Metabolic Process” by altering glycolysis and lipid metabolic pathways in BME fed group as compared to cancer group. In present study, we evaluated the effect of BME on glycolysis and lipid metabolism pathways in human oral cancer cells. METHODS: Cal27 and JHU022 cells were treated with BME. RNA and protein expression were analysed for modulation of glycolytic and lipogenesis genes by quantitative real-time PCR, western blot analyses and immunofluorescence. Lactate and pyruvate level was determined by GC/MS. Extracellular acidification and glycolytic rate were measured using the Seahorse XF analyser. Shotgun lipidomics in Cal27 and JHU022 cell lines following BME treatment was performed by ESI/ MS. ROS was measured by FACS. RESULTS: Treatment with BME on oral cancer cell lines significantly reduced mRNA and protein expression levels of key glycolytic genes SLC2A1 (GLUT-1), PFKP, LDHA, PKM and PDK3. Pyruvate and lactate levels and glycolysis rate were reduced in oral cancer cells following BME treatment. In lipogenesis pathway, we observed a significant reduction of genes involves in fatty acid biogenesis, ACLY, ACC1 and FASN, at the mRNA and protein levels following BME treatment. Further, BME treatment significantly reduced phosphatidylcholine, phosphatidylethanolamine, and plasmenylethanolamine, and reduced iPLA2 activity. Additionally, BME treatment inhibited lipid raft marker flotillin expression and altered its subcellular localization. ER-stress associated CHOP expression and generation of mitochondrial reactive oxygen species were induced by BME, which facilitated apoptosis. CONCLUSION: Our study revealed that bitter melon extract inhibits glycolysis and lipid metabolism and induces ER and oxidative stress-mediated cell death in oral cancer. Thus, BME-mediated metabolic reprogramming of oral cancer cells will have important preventive and therapeutic implications along with conventional therapies. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-6802351
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68023512019-10-22 Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract Sur, Subhayan Nakanishi, Hiroshi Flaveny, Colin Ippolito, Joseph E. McHowat, Jane Ford, David A. Ray, Ratna B. Cell Commun Signal Research BACKGROUND: Metabolic reprogramming is one of the hallmarks of cancer which favours rapid energy production, biosynthetic capabilities and therapy resistance. In our previous study, we showed bitter melon extract (BME) prevents carcinogen induced mouse oral cancer. RNA sequence analysis from mouse tongue revealed a significant modulation in “Metabolic Process” by altering glycolysis and lipid metabolic pathways in BME fed group as compared to cancer group. In present study, we evaluated the effect of BME on glycolysis and lipid metabolism pathways in human oral cancer cells. METHODS: Cal27 and JHU022 cells were treated with BME. RNA and protein expression were analysed for modulation of glycolytic and lipogenesis genes by quantitative real-time PCR, western blot analyses and immunofluorescence. Lactate and pyruvate level was determined by GC/MS. Extracellular acidification and glycolytic rate were measured using the Seahorse XF analyser. Shotgun lipidomics in Cal27 and JHU022 cell lines following BME treatment was performed by ESI/ MS. ROS was measured by FACS. RESULTS: Treatment with BME on oral cancer cell lines significantly reduced mRNA and protein expression levels of key glycolytic genes SLC2A1 (GLUT-1), PFKP, LDHA, PKM and PDK3. Pyruvate and lactate levels and glycolysis rate were reduced in oral cancer cells following BME treatment. In lipogenesis pathway, we observed a significant reduction of genes involves in fatty acid biogenesis, ACLY, ACC1 and FASN, at the mRNA and protein levels following BME treatment. Further, BME treatment significantly reduced phosphatidylcholine, phosphatidylethanolamine, and plasmenylethanolamine, and reduced iPLA2 activity. Additionally, BME treatment inhibited lipid raft marker flotillin expression and altered its subcellular localization. ER-stress associated CHOP expression and generation of mitochondrial reactive oxygen species were induced by BME, which facilitated apoptosis. CONCLUSION: Our study revealed that bitter melon extract inhibits glycolysis and lipid metabolism and induces ER and oxidative stress-mediated cell death in oral cancer. Thus, BME-mediated metabolic reprogramming of oral cancer cells will have important preventive and therapeutic implications along with conventional therapies. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2019-10-21 /pmc/articles/PMC6802351/ /pubmed/31638999 http://dx.doi.org/10.1186/s12964-019-0447-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Sur, Subhayan
Nakanishi, Hiroshi
Flaveny, Colin
Ippolito, Joseph E.
McHowat, Jane
Ford, David A.
Ray, Ratna B.
Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract
title Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract
title_full Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract
title_fullStr Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract
title_full_unstemmed Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract
title_short Inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract
title_sort inhibition of the key metabolic pathways, glycolysis and lipogenesis, of oral cancer by bitter melon extract
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802351/
https://www.ncbi.nlm.nih.gov/pubmed/31638999
http://dx.doi.org/10.1186/s12964-019-0447-y
work_keys_str_mv AT sursubhayan inhibitionofthekeymetabolicpathwaysglycolysisandlipogenesisoforalcancerbybittermelonextract
AT nakanishihiroshi inhibitionofthekeymetabolicpathwaysglycolysisandlipogenesisoforalcancerbybittermelonextract
AT flavenycolin inhibitionofthekeymetabolicpathwaysglycolysisandlipogenesisoforalcancerbybittermelonextract
AT ippolitojosephe inhibitionofthekeymetabolicpathwaysglycolysisandlipogenesisoforalcancerbybittermelonextract
AT mchowatjane inhibitionofthekeymetabolicpathwaysglycolysisandlipogenesisoforalcancerbybittermelonextract
AT forddavida inhibitionofthekeymetabolicpathwaysglycolysisandlipogenesisoforalcancerbybittermelonextract
AT rayratnab inhibitionofthekeymetabolicpathwaysglycolysisandlipogenesisoforalcancerbybittermelonextract